1333379-92-2Relevant academic research and scientific papers
(7-Benzyloxy-2,3-dihydro- 1H -pyrrolo[1,2-a]indol-1-yl)acetic acids as S1P1 functional antagonists
Buzard, Daniel J.,Lopez, Luis,Moody, Jeanne,Kawasaki, Andrew,Schrader, Thomas O.,Kasem, Michelle,Johnson, Ben,Zhu, Xiuwen,Thoresen, Lars,Kim, Sun Hee,Gharbaoui, Tawfik,Sengupta, Dipanjan,Calvano, Lorene,Krishnan, Ashwin,Gao, Yinghong,Semple, Graeme,Edwards, Jeff,Barden, Jeremy,Morgan, Michael,Usmani, Khawja,Chen, Chuan,Sadeque, Abu,Chen, Weichao,Christopher, Ronald J.,Thatte, Jayant,Fu, Lixia,Solomon, Michelle,Whelan, Kevin,Al-Shamma, Hussien,Gatlin, Joel,Gaidarov, Ibragim,Anthony, Todd,Le, Minh,Unett, David J.,Stirn, Scott,Blackburn, Anthony,Behan, Dominic P.,Jones, Robert M.
, p. 1334 - 1339 (2015/02/02)
S1P1 is a validated target for treatment of autoimmune disease, and functional antagonists with superior safety and pharmacokinetic properties are being sought as second generation therapeutics. We describe the discovery and optimization of (7-benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acids as potent, centrally available, direct acting S1P1 functional antagonists, with favorable pharmacokinetic and safety properties.
PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF
-
, (2011/10/03)
The present invention relates to salts, processes, and process intermediates useful in the preparation of (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid of Formula (Ia), salts, and crystalline forms thereof. The compound (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid has been identified as an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).
